Oncolytic virus therapy for prostate cancer

Area of Science:

• Oncology
• Virology
• Biotechnology

Background:

• Oncolytic viruses offer a targeted cancer treatment strategy by selectively replicating within and destroying neoplastic cells.
• This approach leverages the natural or engineered properties of viruses to eliminate cancer while sparing healthy tissues.

Purpose of the Study:

• To review recent advancements in oncolytic virus therapy.
• To summarize the outcomes of clinical trials, particularly for prostate cancer.

Main Methods:

• Classification of oncolytic viruses into DNA and RNA virus groups based on genetic engineering for cancer specificity.
• Analysis of published results from clinical trials involving oncolytic viruses for cancer treatment.

Main Results:

• Oncolytic virus therapy has progressed to clinical trials, with various viral platforms explored.
• For prostate cancer, six clinical trials have reported results, with ongoing studies.
• Phase I studies in prostate cancer patients showed a >25% decrease in serum prostate-specific antigen (PSA) in 58% of patients, with no severe toxicities.

Conclusions:

• Oncolytic virus therapy is a promising strategy for cancer treatment, with demonstrated efficacy and safety in early-phase clinical trials.
• The development of oncolytic viruses, especially for prostate cancer, warrants continued research and clinical investigation.